The Archive · A Source

Janssen Announces U.S. FDA Approval of SPRAVATOTM (esketamine) CIII Nasal Spray

Johnson & Johnson March 5, 2019 www.jnj.com/media-center/press-releases/janssen-announces-u-s-fda-approval-of-spravatotm-esketamine-ciii-nasal-spray-for-adults-with-treatment-resistant-depression-trd-who-have-cycled-through-multiple-treatments-without-relief